Artal Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Artal Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-960,204	Closed	-$7.4M	–	139
2022 Q4	$7.4M	Buy	960,204 +510,204	+113%	+$5M	0.41%	50
2022 Q3	$4.79M	Hold	450,000	–	–	0.2%	61
2022 Q2	$3.66M	Hold	450,000	–	–	0.2%	71
2022 Q1	$3.22M	Buy	450,000 +250,000	+125%	+$2.66M	0.13%	99
2021 Q4	$3.43M	Hold	200,000	–	–	0.09%	118
2021 Q3	$4.6M	Hold	200,000	–	–	0.1%	117
2021 Q2	$7.3M	Buy	+200,000	New	+$5.92M	0.15%	107

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Artal Group's RXRX Position: Q1 2023 in Review

Artal Group sold out of Recursion Pharmaceuticals (RXRX) in Q1 2023, closing a stake of 960,204 shares — an estimated $7.4M sold.

Artal Group first reported a position in RXRX in Q2 2021 and held it in 7 quarters. The position peaked at $7.4M in Q4 2022. 158 funds tracked by Wall St. Rank hold RXRX as of Q1 2023.

Artal Group reported no remaining Recursion Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Artal Group sold 960,204 Recursion Pharmaceuticals shares in Q1 2023, an estimated $7.4M.
Artal Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Artal Group's Recursion Pharmaceuticals position peaked at $7.4M in Q4 2022.
158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.